Please use this identifier to cite or link to this item:
Title: Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
Authors: Kan, Z.
Zheng, H.
Liu, X.
Li, S.
Barber, T.D.
Gong, Z.
Gao, H.
Hao, K.
Willard, M.D.
Xu, J.
Hauptschein, R.
Rejto, P.A.
Fernandez, J.
Wang, G.
Zhang, Q.
Wang, B.
Chen, R.
Wang, J.
Lee, N.P.
Zhou, W.
Lin, Z.
Peng, Z.
Yi, K.
Chen, S.
Li, L.
Fan, X.
Yang, J.
Ye, R.
Ju, J.
Wang, K.
Estrella, H.
Deng, S.
Wei, P.
Qiu, M.
Wulur, I.H.
Liu, J.
Ehsani, M.E.
Zhang, C.
Loboda, A.
Sung, W.K. 
Aggarwal, A.
Poon, R.T.
Fan, S.T.
Wang, J.
Hardwick, J.
Reinhard, C.
Dai, H.
Li, Y.
Luk, J.M.
Mao, M.
Issue Date: Sep-2013
Citation: Kan, Z., Zheng, H., Liu, X., Li, S., Barber, T.D., Gong, Z., Gao, H., Hao, K., Willard, M.D., Xu, J., Hauptschein, R., Rejto, P.A., Fernandez, J., Wang, G., Zhang, Q., Wang, B., Chen, R., Wang, J., Lee, N.P., Zhou, W., Lin, Z., Peng, Z., Yi, K., Chen, S., Li, L., Fan, X., Yang, J., Ye, R., Ju, J., Wang, K., Estrella, H., Deng, S., Wei, P., Qiu, M., Wulur, I.H., Liu, J., Ehsani, M.E., Zhang, C., Loboda, A., Sung, W.K., Aggarwal, A., Poon, R.T., Fan, S.T., Wang, J., Hardwick, J., Reinhard, C., Dai, H., Li, Y., Luk, J.M., Mao, M. (2013-09). Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Research 23 (9) : 1422-1433. ScholarBank@NUS Repository.
Abstract: Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide and has no effective treatment, yet the molecular basis of hepatocarcinogenesis remains largely unknown. Here we report findings from a whole-genome sequencing (WGS) study of 88 matched HCC tumor/normal pairs, 81 of which are Hepatitis B virus (HBV) positive, seeking to identify genetically altered genes and pathways implicated in HBV-associated HCC. We find beta-catenin to be the most frequently mutated oncogene (15.9%) and TP53 the most frequently mutated tumor suppressor (35.2%). TheWnt/beta-catenin and JAK/STAT pathways, altered in 62.5% and 45.5% of cases, respectively, are likely to act as two major oncogenic drivers in HCC. This study also identifies several prevalent and potentially actionable mutations, including activating mutations of Janus kinase 1 ( JAK1), in 9.1% of patients and provides a path toward therapeutic intervention of the disease. © 2013, Published by Cold Spring Harbor Laboratory Press.
Source Title: Genome Research
ISSN: 10889051
DOI: 10.1101/gr.154492.113
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Feb 17, 2020


checked on Feb 17, 2020

Page view(s)

checked on Feb 17, 2020

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.